Patients with D2T-PsA can be stratified into inflammatory and noninflammatory phenotypes, with the former linked to higher sonographic activity.

Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

A subset of patients with PsA achieved rapid and sustained remission following treatment with b/tsDMARDs and were classified as a super-responder phenotype.

Recently, researchers in Australia tested baricitinib, a drug used for rheumatoid arthritis, in people newly diagnosed with ...

Research team from the universities of Southampton and Keele, working alongside the NHS and Versus Arthritis A new project ...